Mature Epstein-Barr virus (EBV) was purified from the culture medium of infected lymphocytes made functionally conditional for Zta activation of lytic replication by an in-frame fusion with a mutant estrogen receptor. Proteins in purified virus preparations were separated by gradient gel electrophoresis and trypsin-digested; peptides were then analyzed by tandem hydrophobic chromatography, tandem MS sequencing, and MS scans. Potential peptides were matched with EBV and human gene ORFs. Mature EBV was mostly composed of homologues of proteins previously found in a herpes virion. However, EBV homologues to herpes simplex virus capsid-associated or tegument components UL7 (BBRF2), UL14 (BGLF3), and EBV BFRF1 were not significantly detected. Instead, probable tegument components included the EBV and ␥-herpesvirus-encoded BLRF2, BRRF2, BDLF2 and BKRF4 proteins. Actin was also a major tegument protein, and cofilin, tubulin, heat shock protein 90, and heat shock protein 70 were substantial components. EBV envelope glycoprotein gp350 was highly abundant, followed by glycoprotein gH, intact and furincleaved gB, gM, gp42, gL, gp78, gp150, and gN. BILF1 (gp64) and proteins associated with latent EBV infection were not detected in virions.lymphocyte ͉ proteomics ͉ virion ͉ herpes virus T he experiments reported here determine the protein composition of mature enveloped Epstein-Barr (EB) virus (EBV). EBV protein composition has not been systematically studied since the proteins of purified enveloped and deenveloped EBV were initially displayed on polyacrylamide gels. Except for glycoproteins, EB virion protein annotations have usually been based on DNA sequence homology to a characterized herpesvirus ORF, with verification for EBV in specific instances.EBV is a ␥1-herpesvirus. The ␥1-and ␥2-herpesvirus genomes are mostly collinear and share smaller conserved gene clusters with ␣-and -herpesvirus genomes. Herpesvirus family-conserved genes mostly encode proteins that are important for DNA replication, virus morphogenesis, or virion composition. Conserved herpesvirus genes are known to encode 5 capsid proteins, 5 envelope proteins, and 10 tegument proteins in at least one herpesvirus (1, 2). Accordingly, EBV BcLF1, BDLF1, BFRF3, BORF1, and BBRF1 ORFs are likely to encode the major, minor, and smallest capsid proteins (MCP, mCP, and sCP, respectively); the mCP-binding protein (mCPBP); and portal. Furthermore, the EBV BPLF1, BOLF1, BVRF1, BGLF1, BGLF4, BGLF2, BBRF2, BSRF1, BGLF3, and BBLF1 ORFs are likely to encode tegument proteins (3-5). EBV BNRF1 and BLRF2 probably encode ␥-herpesvirus-unique tegument proteins (Table 1) (6-8). The EBV homologues of gB (BALF4), gH (BXLF2), and gL (BKRF2) have been detected by specific antibodies in EB virions. Moreover, EBV BLLF1, BZLF2, and BDLF3 ORF-specific antibodies have detected EBV-unique gp350, gp42, and gp150 in the virus (Table 1) (9). EBV BMRF2-encoded protein may also be in virus envelopes because it has an RGD (arginine-glycine-aspartic acid) motif that may be a ligand for an int...
The natural history of cancers associated with virus exposure is intriguing, since only a minority of human tissues infected with these viruses inevitably progress to cancer. However, the molecular reasons why the infection is controlled or instead progresses to subsequent stages of tumorigenesis are largely unknown. In this article, we provide the first complete DNA methylomes of double-stranded DNA viruses associated with human cancer that might provide important clues to help us understand the described process. Using bisulfite genomic sequencing of multiple clones, we have obtained the DNA methylation status of every CpG dinucleotide in the genome of the Human Papilloma Viruses 16 and 18 and Human Hepatitis B Virus, and in all the transcription start sites of the Epstein-Barr Virus. These viruses are associated with infectious diseases (such as hepatitis B and infectious mononucleosis) and the development of human tumors (cervical, hepatic, and nasopharyngeal cancers, and lymphoma), and are responsible for 1 million deaths worldwide every year. The DNA methylomes presented provide evidence of the dynamic nature of the epigenome in contrast to the genome. We observed that the DNA methylome of these viruses evolves from an unmethylated to a highly methylated genome in association with the progression of the disease, from asymptomatic healthy carriers, through chronically infected tissues and pre-malignant lesions, to the full-blown invasive tumor. The observed DNA methylation changes have a major functional impact on the biological behavior of the viruses.
Lymphoblastoid cell lines (LCLs), originally collected as renewable sources of DNA, are now being used as a model system to study genotype–phenotype relationships in human cells, including searches for QTLs influencing levels of individual mRNAs and responses to drugs and radiation. In the course of attempting to map genes for drug response using 269 LCLs from the International HapMap Project, we evaluated the extent to which biological noise and non-genetic confounders contribute to trait variability in LCLs. While drug responses could be technically well measured on a given day, we observed significant day-to-day variability and substantial correlation to non-genetic confounders, such as baseline growth rates and metabolic state in culture. After correcting for these confounders, we were unable to detect any QTLs with genome-wide significance for drug response. A much higher proportion of variance in mRNA levels may be attributed to non-genetic factors (intra-individual variance—i.e., biological noise, levels of the EBV virus used to transform the cells, ATP levels) than to detectable eQTLs. Finally, in an attempt to improve power, we focused analysis on those genes that had both detectable eQTLs and correlation to drug response; we were unable to detect evidence that eQTL SNPs are convincingly associated with drug response in the model. While LCLs are a promising model for pharmacogenetic experiments, biological noise and in vitro artifacts may reduce power and have the potential to create spurious association due to confounding.
, and -2B), of the BamA rightward transcripts (BARTs), and of small RNAs (EBERs) and by infected cell proliferation. A robust T-lymphocyte immune response eliminates most latency III-infected cells. Subsequently, EBV persists in resting memory B lymphocytes that express EBNA1, LMP2a, EBERs, and BARTs (17,68,85). EBNA1 is protected from proteosome degradation and is not presented by major histocompatibility complex (MHC) class I on the infected cell surface, enabling infected cells to evade CD8 ϩ cytotoxic T lymphocytes. High-level T-lymphocyte immunity to latency III-infected B lymphocytes persists for life. In the absence of an effective immune response, infected B lymphocytes can proliferate without restraint and cause malignant lymphoproliferative diseases. EBV-associated lymphoproliferative diseases occur with primary infection after organ transplantation or in previously infected people with profound immune suppression for transplantation or as a consequence of AIDS (reviewed in reference 76).EBV infection of B lymphocytes in vitro also results in latency III and sustained cell proliferation as lymphoblastoid cell lines (LCLs). EBV reverse genetic analyses in the context of primary B-lymphocyte outgrowth into LCLs indicate that EBNA2, EBNALP, EBNA3A, EBNA3C, and LMP1 are the critical EBV genes for LCL growth and survival. Latency III induces B-lymphocyte proliferation and survival by constitutively activating cellular signaling pathways. EBNA2, -LP, -3A, -3B, and -3C associate with the cellular protein RBP-J/CBF1 and regulate the transcription of promoters that are downstream of Notch receptor signaling, whereas LMP1 associates with tumor necrosis factor receptor-associated factors (TRAFs), tumor necrosis factor receptor-associated death domain protein (TRADD), and receptor-interacting protein (RIP), and activates the NF-B and stress activated kinase pathways (reviewed in reference 50).The objective of the studies reported here is to further assess the importance of NF-B and LMP1 in LCL survival and in the overall effects of latency III-regulated cell gene expression. Mutations of the LMP1 C-terminal TRAF or TRADD/RIP engagement sites render LMP1 ineffective in LCL outgrowth and diminish [46][47][48]. NF-B inhibition in two LCL cell lines that have been in culture for many years resulted in IB4 LCL apoptosis and sensitization of an
The ubiquitous Epstein Barr virus (EBV) exploits human B-cell development to establish a persistent infection in B90% of the world population. Constitutive activation of NF-jB by the viral oncogene latent membrane protein 1 (LMP1) has an important role in persistence, but is a risk factor for EBV-associated lymphomas. Here, we demonstrate that endogenous LMP1 escapes degradation upon accumulation within intraluminal vesicles of multivesicular endosomes and secretion via exosomes. LMP1 associates and traffics with the intracellular tetraspanin CD63 into vesicles that lack MHC II and sustain low cholesterol levels, even in 'cholesterol-trapping' conditions. The lipid-raft anchoring sequence FWLY, nor ubiquitylation of the N-terminus, controls LMP1 sorting into exosomes. Rather, C-terminal modifications that retain LMP1 in Golgi compartments preclude assembly within CD63-enriched domains and/or exosomal discharge leading to NF-jB overstimulation. Interference through shRNAs further proved the antagonizing role of CD63 in LMP1-mediated signalling. Thus, LMP1 exploits CD63-enriched microdomains to restrain downstream NFjB activation by promoting trafficking in the endosomalexosomal pathway. CD63 is thus a critical mediator of LMP1 function in-and outside-infected (tumour) cells.
Summary Epstein-Barr virus (EBV) causes Burkitt, Hodgkin, and post-transplant B cell lymphomas. How EBV remodels metabolic pathways to support rapid B cell outgrowth remains largely unknown. To gain insights, primary human B cells were profiled by tandem-mass-tag-based proteomics at rest and at nine time points after infection; >8,000 host and 29 viral proteins were quantified, revealing mitochondrial remodeling and induction of one-carbon (1C) metabolism. EBV-encoded EBNA2 and its target MYC were required for upregulation of the central mitochondrial 1C enzyme MTHFD2, which played key roles in EBV-driven B cell growth and survival. MTHFD2 was critical for maintaining elevated NADPH levels in infected cells, and oxidation of mitochondrial NADPH diminished B cell proliferation. Tracing studies underscored contributions of 1C to nucleotide synthesis, NADPH production, and redox defense. EBV upregulated import and synthesis of serine to augment 1C flux. Our results highlight EBV-induced 1C as a potential therapeutic target and provide a new paradigm for viral onco-metabolism.
The nuclear factor B (NF-κB) subunits RelA, RelB, cRel, p50 and p52 are each critical for B-cell development and function. To systematically characterize their responses to canonical and non-canonical NF-κB pathway activity, we performed ChIP-seq analysis in lymphoblastoid B-cells (LCLs). We found a complex NF-κB binding landscape, which did not readily reflect the two NF-κB pathway paradigm. Instead, ten subunit binding patterns were observed at promoters and eleven at enhancers. Nearly one-third of NF-κB binding sites lacked κB motifs and were instead enriched for alternative motifs. The oncogenic forkhead box protein FOXM1 co-occupied nearly half of NF-κB binding sites, and was identified in protein complexes with NF-κB on DNA. FOXM1 knockdown decreased NF-κB target gene expression, and ultimately induced apoptosis, highlighting FOXM1 as a synthetic lethal target in B-cell malignancy. These studies provide a resource for understanding mechanisms that underlie NF-κB nuclear activity, and highlight opportunities for selective NF-κB blockade.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.